Loss of lectin-like activity in aberrant type 1 fimbriae of Escherichia coli.

Infection and Immunity
B I EisensteinE H Beachey

Abstract

Growth of a streptomycin-resistant strain of Escherichia coli (VL-2) in the presence of 30 microgram of streptomycin per ml resulted in the production by these bacteria of structurally altered, nonfunctional type 1 fimbriae. This strain, when grown in this subinhibitory concentration of streptomycin, became incapable of producing mannose-sensitive hemagglutination (<1% of that of the control). Adhering ability to epithelial cells and human leukocytes was also diminished (42 and 7% of that of the control, respectively). Although these streptomycin-treated bacteria were as heavily fimbriated as untreated bacteria, their fimbriae were significantly longer. Furthermore, in contrast to the fimbriae of the untreated bacteria, those isolated from the drug-treated bacteria were found to lack mannose binding activity as measured by hemagglutination. It appears, therefore, that streptomycin can cause even resistant bacteria to produce an aberrant fimbrial protein, possibly by causing misreading of messenger RNA. These studies indicate that the use of sublethal doses of certain antibiotics whose mode of action is well known may shed light on the genetic and chemical modulation of bacterial factors involved in mucosal colonization.

References

Sep 1, 1979·Infection and Immunity·F J Silverblatt
Jan 1, 1977·Cell·P Edelmann, J Gallant
May 1, 1975·The Journal of Experimental Medicine·I OfekG L Campbell
Sep 9, 1977·Biochemical and Biophysical Research Communications·Z Bar-ShavitN Sharon
Nov 1, 1977·The Journal of Experimental Medicine·I E Salit, E C Gotschlich
Oct 1, 1978·Infection and Immunity·I Ofek, E H Beachey
Jul 1, 1979·The Journal of Clinical Investigation·F J Silverblatt, L S Cohen

❮ Previous
Next ❯

Citations

May 1, 1993·Diagnostic Microbiology and Infectious Disease·S A Sonstein, J C Burnham
Nov 1, 1988·Antimicrobial Agents and Chemotherapy·D M Schifferli, E H Beachey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.